<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424213</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00091092</org_study_id>
    <nct_id>NCT03424213</nct_id>
  </id_info>
  <brief_title>Race-related Alternative Splicing: Novel Targets in Prostate Cancer</brief_title>
  <acronym>PCaP splicing</acronym>
  <official_title>Race-related Alternative Splicing: Novel Targets in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led&#xD;
      to the discovery of alternative splicing as a novel molecular mechanism underlying more&#xD;
      aggressive PCa in AA men. Coded archival radical prostatectomy tissue specimens and annotated&#xD;
      clinical data, questionnaire data, and ancestral genotyping data will be obtained from the&#xD;
      racially diverse and federally funded North Carolina-Louisiana PCa Project (NC-LA PCaP). We&#xD;
      will use 33 tissue specimens from each of the following 6 groups (n=198 total): white low&#xD;
      aggressive, white intermediate aggressive, white high aggressive, AA low aggressive, AA&#xD;
      intermediate aggressive and AA high aggressive. The aforementioned tissues will first be&#xD;
      screened for tumor content and Gleason grade by a genitourinary pathologist. To identify&#xD;
      race-related splice variants, RNA will be isolated for targeted sequencing of prioritized&#xD;
      race-related alternatively spliced genes using the NimbleGen SeqCap Target Enrichment, SeqCap&#xD;
      RNA System to capture regions of interest and the Illumina HiSeq sequencing platform to&#xD;
      sequence these regions at a depth and coverage sufficient to accurately call alternative&#xD;
      splicing events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of candidate race-related splice variants in localized prostate cancer of varying degrees of aggressiveness</measure>
    <time_frame>at the time of analysis</time_frame>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>white low aggressive</arm_group_label>
    <description>low aggressive = Gleason score &lt; 7 and stage cT1-cT2 and PSA &lt; 10 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>white high aggressive</arm_group_label>
    <description>high aggressive = Gleason score ≥ 8 or PSA &gt; 20 ng/ml or Gleason score = 7 and stage cT3-cT4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>white intermediate aggressive</arm_group_label>
    <description>intermediate aggressive = all other cases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA low aggressive</arm_group_label>
    <description>low aggressive = Gleason score &lt; 7 and stage cT1-cT2 and PSA &lt; 10 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA high aggressive</arm_group_label>
    <description>high aggressive = Gleason score ≥ 8 or PSA &gt; 20 ng/ml or Gleason score = 7 and stage cT3-cT4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA intermediate aggressive</arm_group_label>
    <description>intermediate aggressive = all other cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions - retrospective data collection</intervention_name>
    <description>No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data</description>
    <arm_group_label>AA high aggressive</arm_group_label>
    <arm_group_label>AA intermediate aggressive</arm_group_label>
    <arm_group_label>AA low aggressive</arm_group_label>
    <arm_group_label>white high aggressive</arm_group_label>
    <arm_group_label>white intermediate aggressive</arm_group_label>
    <arm_group_label>white low aggressive</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      radical prostatectomy specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes AA and white male patients having confirmed prostate cancer&#xD;
        and enrolled in NC-LA PCaP, a population-based, case-only study of prostate cancer in AA&#xD;
        and white men in NC and LA. Radical prostatectomy specimens will be selected from AA and&#xD;
        white patients who have consented to NC-LA PCaP and have adequate tumor specimens of&#xD;
        appropriate aggressiveness banked.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of prostate cancer.&#xD;
&#xD;
          2. Self-reported race of AA or white.&#xD;
&#xD;
          3. Availability of five unstained slides per radical prostatectomy specimen and an&#xD;
             associated Hematoxylin and Eosin stained slide for each radical prostatectomy specimen&#xD;
             from NC-LA PCaP.&#xD;
&#xD;
          4. Classification of prostate cancer of low, intermediate or high aggressiveness, as&#xD;
             defined by NC-LA PCaP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Obtained radical prostatectomy tissue is inadequate for RNA analysis and/or is not&#xD;
        positive for adenocarcinoma of the prostate of low, intermediate or high aggressiveness.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Patierno, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Freedman, PhD</last_name>
    <phone>919-684-6354</phone>
    <email>Jennifer.Freedman@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Freedman, PhD</last_name>
      <phone>919-684-6354</phone>
      <email>Jennifer.Freedman@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

